Clinical Trial Update: Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pitavastatin for reducing cardiovascular risk in HIV-infected adults has completed, with results posted in October 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• HIV Infection

Drugs mentioned

• Pitavastatin (Pitavastatin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV, Cardiovascular Diseases | Phase 3 | Status: COMPLETED | Results posted: 2024-10-15